Home Companies Catalysts Deep Dives
Lixiana edoxaban APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Launch2015-01-08
Peak Sales Est$2000M
Formulations[{"id":"lixiana-oral","doses":"15mg, 30mg, 60mg tablets","route":"Oral","setting":"PATIENT_SELF","fr
Companies
DSNKY (ORIGINATOR)100%
Mechanism: Factor Xa inhibitor
Expert: Direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa, a key enzyme in the coagulation cascade. Once-daily dosing with predictable pharmacokinetics.
Everyday: A blood thinner that blocks Factor Xa, preventing blood clots from forming. Used to prevent strokes in patients with irregular heartbeats.
Targets: ["FACTOR XA"]
Revenue History
PeriodRevenue ($M)
2023$2,156M
2024$2,312M
Q1 2025$590M
Programs (4)
IndicationStageKey StudyRegional Status
VTEAPPROVEDHokusai-VTE[{"stage":"APPROVED","region":"EU","approval_date":"2015-06-19"},{"stage":"APPRO
AFibAPPROVEDENGAGE AF-TIMI 48[{"stage":"APPROVED","region":"EU","approval_date":"2015-06-19"},{"stage":"APPRO
NVAFAPPROVEDENGAGE AF-TIMI 48[{"stage":"APPROVED","region":"US","approval_date":"2015-01-08"},{"stage":"APPRO
VTEAPPROVEDHokusai-VTE[{"stage":"APPROVED","region":"US","approval_date":"2015-01-08"},{"stage":"APPRO
Upcoming Catalysts (1)
Lixiana - Patent Expiration Preparation Ongoing
Notes
Once-daily oral anticoagulant (DOAC). Approved for stroke prevention in AFib and VTE treatment/prevention. Marketed as Savaysa in US. Mature product with LOE approaching.
Data from Supabase · Updated 2026-03-24